Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
AstraZeneca |
---|---|
Information provided by: | AstraZeneca |
ClinicalTrials.gov Identifier: | NCT00060489 |
The purpose of this study is to evaluate the efficacy and safety of quetiapine in the treatment of a major depressive episode in patients with bipolar disorder.
Condition | Intervention | Phase |
---|---|---|
Bipolar Disorder Depression, Bipolar |
Drug: SEROQUEL (quetiapine fumarate) Tablets |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment |
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | 5077US/0049 |
Study First Received: | May 6, 2003 |
Last Updated: | June 23, 2005 |
ClinicalTrials.gov Identifier: | NCT00060489 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Bipolar Depression |
Depression Tranquilizing Agents Bipolar Disorder Psychotropic Drugs Central Nervous System Depressants Depressive Disorder Antipsychotic Agents |
Behavioral Symptoms Affective Disorders, Psychotic Quetiapine Mental Disorders Mood Disorders Psychotic Disorders |
Depression Tranquilizing Agents Bipolar Disorder Physiological Effects of Drugs Psychotropic Drugs Central Nervous System Depressants Depressive Disorder Antipsychotic Agents |
Pharmacologic Actions Behavioral Symptoms Affective Disorders, Psychotic Quetiapine Mental Disorders Therapeutic Uses Mood Disorders Central Nervous System Agents |